These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7635096)

  • 21. Anticonvulsant activity of metabolites of valproic acid.
    Löscher W
    Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):158-63. PubMed ID: 6784685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. I. Biochemical, histopathological and pharmacokinetic studies.
    Löscher W; Wahnschaffe U; Hönack D; Wittfoht W; Nau H
    Epilepsy Res; 1992 Dec; 13(3):187-98. PubMed ID: 1493781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ("controlled release") administration in a model of generalized seizures in rats.
    Löscher W; Hönack D
    Epilepsia; 1995 Sep; 36(9):929-37. PubMed ID: 7649133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat.
    Pollack GM; Shen DD
    J Pharmacol Methods; 1985 Apr; 13(2):135-46. PubMed ID: 3920448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of valproate analogues in rats. I. Spiro[4.6]undecane-2-carboxylic acid.
    Liu MJ; Scott KR; Pollack GM
    Epilepsia; 1990; 31(4):465-73. PubMed ID: 2114971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study.
    Scism JL; Powers KM; Artru AA; Lewis L; Shen DD
    Brain Res; 2000 Nov; 884(1--2):77-86. PubMed ID: 11082489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts.
    Yang L; Lin IH; Ting CT; Tsai TH
    J Ethnopharmacol; 2021 Oct; 278():114276. PubMed ID: 34082013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of sodium valproate on proton MRS visible neurochemical concentrations.
    Simister RJ; McLean MA; Barker GJ; Duncan JS
    Epilepsy Res; 2007 May; 74(2-3):215-9. PubMed ID: 17448636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The involvement of taurine in the action mechanism of sodium valproate (VPA) in the treatment of epilepsy.
    Anyanwu E; Harding GF
    Acta Physiol Pharmacol Ther Latinoam; 1993; 43(1-2):20-7. PubMed ID: 7865870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates.
    Tang W; Abbott FS
    Chem Res Toxicol; 1996 Mar; 9(2):517-26. PubMed ID: 8839057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids.
    Silva MF; Ruiter JP; IJlst L; Jakobs C; Duran M; de Almeida IT; Wanders RJ
    Chem Biol Interact; 2001 Sep; 137(3):203-12. PubMed ID: 11566289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beneficial interaction between vigabatrin and valproate against seizures induced by pentylenetetrazole in mice.
    Cuadrado A; Armijo JA
    Pharmacol Res; 2005 May; 51(5):489-96. PubMed ID: 15749465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites.
    Nau H; Helge H; Luck W
    J Pediatr; 1984 Apr; 104(4):627-34. PubMed ID: 6423793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals.
    Löscher W
    Pharm Weekbl Sci; 1992 Jun; 14(3A):139-43. PubMed ID: 1502015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U
    Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time course of alpha-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal gamma-aminobutyric acid levels in comparison to valproic acid.
    Tang W; Palaty J; Abbott FS
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1163-72. PubMed ID: 9316822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concentration of metabolites of valproic acid in plasma of epileptic patients.
    Löscher W
    Epilepsia; 1981 Apr; 22(2):169-78. PubMed ID: 6781893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy.
    Reddy DS; Rogawski MA
    Epilepsia; 2001 Mar; 42(3):337-44. PubMed ID: 11442150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
    Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.